Editorial introductions : Current Opinion in Nephrology and Hypertension

Secondary Logo

Journal Logo


Editorial introductions

Editor(s): Brown, Nancy J.; Goldfarb, David S.

Current Opinion in Nephrology and Hypertension 32(2):p v-vi, March 2023. | DOI: 10.1097/MNH.0000000000000868
  • Free

Current Opinion in Nephrology and Hypertension was launched in 1992. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of nephrology and hypertension is divided into 12 sections that are each reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.


Nancy J. Brown

Nancy J. Brown

Nancy J. Brown, MD is the Jean and David W. Wallace Dean of Yale School of Medicine, USA, and the C.N.H. Long Professor of Internal Medicine. Prior to assuming the role of dean at Yale in 2020, Dr Brown served for nine years as the Chair of the Department of Medicine at Vanderbilt University Medical Centre, Tennessee, USA, where she established herself as a national leader in the development of infrastructure to promote the career success of physician-scientists. She founded the Vanderbilt Master of Science in Clinical Investigation program in 2000, served as Associate Dean for Clinical and Translational Scientist Development at Vanderbilt from 2006 to 2010, and as Director of the Division of Clinical Pharmacology from 2009 to 2010.

Dr Brown's NIH-funded research focuses on cardiovascular pharmacology and vascular biology in humans. She is particularly interested in understanding the mechanisms of anti-hypertensive and anti-diabetic drugs that are peptidase inhibitors, including the angiotensin-converting enzyme inhibitors, dipeptidyl peptidase 4 inhibitors, and neprilysin inhibitors. Her group has elucidated not only how these drugs decrease inflammation, enhance fibrinolysis (the breakdown of blood clots), and improve glucose homeostasis, but also how they interact with one another and sometimes cause side effects. This understanding leads to optimizing outcomes in patients with hypertension and diabetes.

Dr Brown received her A. B. in Molecular Biophysics and Biochemistry from Yale and her MD from Harvard Medical School, USA. She completed her clinical training and a fellowship in clinical pharmacology at Vanderbilt University, Tennessee, USA. Dr Brown is a Fellow of the American Association for the Advancement of Science and a member of the American Society of Clinical Investigation, the Association of American Physicians, the National Academy of Medicine, and the American Academy of Arts and Sciences. She is a Master of the American College of Physicians and a fellow of the Royal College of Physicians. She has served on the National Advisory Research Resources Council and the National Heart, Lung, and Blood Advisory Council of the National Institutes of Health. Dr Brown currently serves on the visiting committee for Harvard Medical School and the External Advisory Board for the Harvard-MIT Health Sciences and Technology program. She is a member of the Scientific Advisory Board of Alnylam Pharmaceuticals.

David S. Goldfarb

David S. Goldfarb

David S. Goldfarb, MD is Professor of Medicine and Physiology at New York University Grossman School of Medicine, USA. He is the Clinical Chief of the Nephrology Division at New York University Langone Health, and Chief of the Nephrology Section and Director of the Hemodialysis Unit at the New York VA Medical Center in Manhattan, USA. He serves as the Director of the Kidney Stone Prevention Programs at NYU Langone and at New York VA Medical Center, USA. He graduated from Yale College and the Yale School of Medicine, USA, and trained in Internal Medicine at New York VA and New York University, USA, and Nephrology at New York University, USA. He teaches first year renal physiology and renal pathophysiology at NYU, where he has been Teacher of the Year on 3 occasions. Dr Goldfarb is an internationally renowned expert in kidney stone prevention. He is a principal investigator of the Rare Kidney Stone Consortium. Dr Goldfarb is the former President of the NY Society of Nephrology and of the ROCK Society (Research on Calculus Kinetics). He was vice-chair of the American Urological Association's guideline panel, representing the American Society of Nephrology, on Medical Management of Kidney Stones. He is a co-inventor of Moonstone, the first high citrate beverage. He was selected as “Stone Crusher of the Year” in 2014 by the Oxalosis and Hyperoxaluria Foundation and “Nephrologist of the Year” in 2016 by the American Kidney Fund. He has had three calcium oxalate stones.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.